為持續強化我國以科學實證為基礎之醫療決策模式，在衛生福利部見證下，衛生福利部中央健康保險署（下稱健保署）與財團法人醫藥品查驗中心（CDE）於今（2026）年5月11日與英國國家健康暨照護卓越研究院（National Institute for Health and Care Excellence, NICE）續簽合作協議，展開新一階段臺英醫療科技評估合作，將結合我國國家醫療科技評估中心行政法人立法，全面推動創新醫療之科技評估架構、醫療數位轉型、醫療科技人才培育與導入社會觀點決策。
      NICE 為全球醫療科技評估機構的重要典範，以其嚴謹、實證導向且透明的醫療科技評估方法聞名，並在全球醫療科技評估方法學的發展上居於領導地位。我國於2023年5月在石崇良部長擔任健保署長任內與NICE簽訂合作協議後，已成功將多項國際經驗轉化為在地政策工具，包含：參考英國「癌症藥品基金（Cancer Drugs Fund）」機制，推動我國癌症新藥暫時性支付專款，建立兼顧病人新藥可近性與健保財務永續性的彈性；同時積極推動設立行政法人-國家醫療科技評估中心，目前相關法制作業已進入立法院審議階段。
      本次合作協議在石部長見證下由陳亮妤署長代表續簽，亦將配合我國醫療科技評估未來發展方向，規劃2026年至2028年三年合作重點，聚焦於四大政策主軸：
一、強化創新醫療科技評估與給付制度：精進暫時性支付與再評估制度，建立高價創新療法（如基因與細胞治療）之HTA評估架構，以有效管控長期醫療效益之不確定性。
二、癌症數位治理經驗分享：雙方分享如何透過癌症治療數位轉型，推動FHIR（Fast Healthcare Interoperability Resources）國際標準格式，以加速事前審查及建立真實世界癌症治療效益動態評估機制。
三、培育專業人才並深化國際合作：透過教育訓練、專家交流及資訊網絡合作，持續提升我國HTA專業能力。
四、導入社會觀點（Societal Perspective）：強化醫療、長照與社會照護資源整合與政策評估能力。
      石崇良部長表示，藉由推動成立行政法人-國家醫療科技評估中心，並與國際頂尖HTA組織結盟，將進一步強化以科學實證基礎之衛生福利決策架構，實踐健康台灣的政策承諾；並期許未來我國能在亞太及全球HTA網絡扮演關鍵角色。
      健保署陳亮妤署長表示，透過與國際HTA頂尖機構NICE之持續合作，將進一步強化我國健保醫療科技評估、給付制度與醫療資訊數位化三者之整合，提升醫療數據治理效能，並促進醫療資源的合理配置，確保全民健保制度的永續發展。

※欲了解更多關於NICE的資訊，請參閱NICE官方網站：www.nice.org.uk


▲圖說：衛生福利部石崇良部長(中間)、中央健康保險署陳亮妤署長（左）、財團法人醫藥品查驗中心劉明勳執行長(右)

▲圖說：英國NICE Advice Director , Brad Groves(左上)、英國NICE Adviser , Juan Yanguela(右下)、英國NICE Project Coordinator , Abigail Bourne (右上)

Taiwan and NICE Renew Partnership Agreement to Deepen Taiwan–UK Healthcare Policy Collaboration
To further strengthen Taiwan’s evidence-based healthcare decision-making framework, under the witness of the Ministry of Health and Welfare (MOHW), Taiwan’s National Health Insurance Administration (NHIA) and the Center for Drug Evaluation (CDE) renewed their partnership agreement with the UK National Institute for Health and Care Excellence (NICE) on May 11, 2026. The renewed agreement marks the beginning of a new phase of Taiwan–UK collaboration on Health Technology Assessment (HTA), aligned with Taiwan’s ongoing legislative efforts to establish the Center for Health Technology Assessment as an administrative corporation. The collaboration will focus on advancing innovative healthcare assessment frameworks, healthcare digital transformation, HTA talent development, and the incorporation of societal perspectives into healthcare decision-making. 
NICE is widely recognised as one of the leading global HTA organisations, renowned for its rigorous, evidence-based and transparent approach to health technology assessment, and its work at the forefront of HTA methodology globally. 
Following the signing of the initial partnership agreement in May 2023, during Minister Chung-Liang Shih’s tenure as Director-General of the NHIA, Taiwan has successfully translated several international experiences into local policy tools. These include the establishment of Taiwan’s Provisional payment for innovative cancer drugs, inspired by the UK Cancer Drugs Fund (CDF), to improve patient access to new therapies while maintaining the sustainability of the National Health Insurance system. Taiwan has also actively promoted the establishment of the Center for Health Technology Assessment as a non-departmental public body, with related legislation currently under review by the Legislative Yuan.
The renewed agreement, witnessed by Minister Chung-Liang Shih and signed by NHIA Director-General Lian-Yu Chen, outlines the key areas of collaboration for 2026–2028, focusing on four major policy priorities:
Strengthening HTA and reimbursement systems for innovative healthcare technologies:
Enhancing Provisional payment and reassessment mechanisms, and establishing HTA frameworks for high-cost innovative therapies, such as gene and cell therapies, to better manage uncertainties regarding long-term clinical outcomes.
Sharing experiences in digital governance for cancer care:
Promoting healthcare digital transformation through the adoption of FHIR (Fast Healthcare Interoperability Resources) international standards to accelerate prior authorization processes and establish dynamic real-world evaluation systems for cancer treatment outcomes.
Developing professional talent and deepening international collaboration:
Continuing to strengthen Taiwan’s HTA capacity through training programs, expert exchanges, and information network collaboration.
Incorporating societal perspectives into healthcare decision-making:
Enhancing policy evaluation and integration across healthcare, long-term care, and social care resources.
Minister Chung-Liang Shih stated that the establishment of the Center for Health Technology Assessment as a non-departmental public body, together with strategic partnerships with leading international HTA organizations, will further strengthen Taiwan’s evidence-based health and welfare policymaking framework and support the vision of Healthy Taiwan Policy. He also expressed hope that Taiwan will continue to play a key role within regional and global HTA networks in the future.
NHIA Director-General Lian-Yu Chen noted that continued collaboration with NICE, one of the world’s leading HTA organizations, will further strengthen the integration of HTA, reimbursement systems, and healthcare digitalization in Taiwan, enhance healthcare data governance, promote efficient healthcare resource allocation, and ensure the sustainability of Taiwan’s National Health Insurance system.
※For more information about NICE, please visit the official NICE website: www.nice.org.uk

▲From left: Director General Lian-Yu Chen of the National Health Insurance Administration (NHIA), Minister of Health and Welfare Chung-Liang Shih, and Chief Executive Director Ming-Hsun Liu of the center for Drug Evaluation (CDE)

▲A screenshot of the virtual conference, clockwise from top left: NICE Advice Director Brad Groves, NICE Project Coordinator Abigail Bourne, NICE Adviser Juan Yanguela